Aylin Alasonyalilar Demirer

Aylin Alasonyalilar Demirer

Auto-generated profile, based on publicly available information

Aylin Alasonyalilar Demirer

Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in The Prostate
Verified
Journal Article
Closed access
PDF file
SESaid M. Elshafae
Said M. Elshafae
WDWessel P. Dirksen
Wessel P. Dirksen
AAAylin Alasonyalilar‐Demirer
Aylin Alasonyalilar‐Demirer
JBJustin Breitbach
Justin Breitbach
SYShiyu Yuan
Shiyu Yuan
TRThomas Rosol
Thomas Rosol

8 October 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
NKNicole A. Kohart
Nicole A. Kohart
SESaid M. Elshafae
Said M. Elshafae
ADAylin A. Demirer
Aylin A. Demirer
WDWessel P. Dirksen
Wessel P. Dirksen
JBJustin T. Breitbach
Justin T. Breitbach
TRThomas Rosol
Thomas Rosol
Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) are important factors that increase bone resorption and hypercalcemia in adult T-cell leukemia (ATL). We investigated the role of PTHrP and MIP-1α in the development of local osteolytic lesions in T-cell leukemia through overexpression in Jurkat T-cells. Injections of Jurkat-PTHrP and Jurkat-MIP-1α into the tibia and the left ventricle of NSG mice were performed to evaluate tumor growth and metastasis in vivo. Jurkat-pcDNA tibial neoplasms grew at a significantly greater rate and total tibial tumor burden was significantly greater than Jurkat-PTHrP neoplasms. Despite the lower tibial tumor burden, Jurkat-PTHrP bone neoplasms had significantly greater osteolysis than Jurkat-pcDNA and Jurkat-MIP-1α neoplasms. Jurkat-PTHrP and Jurkat-pcDNA cells preferentially metastasized to bone following intracardiac injection, though the overall metastatic burden was lower in Jurkat-PTHrP mice. These findings demonstrate that PTHrP induced pathologic osteolysis in T-cell leukemia but did not increase the incidence of skeletal metastasis.

5 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
AKAdam McLain Kase
Adam McLain Kase
JGJustyna Gleba
Justyna Gleba
JMJames L. Miller
James L. Miller
EMErin Miller
Erin Miller
JPJoachim Petit
Joachim Petit
JCJohn A. Copland
John A. Copland
Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive malignancy with poor outcomes. To investigate novel therapeutic strategies, we characterized three new metastatic prostate cancer patient derived-tumor xenograft (PDTX) models and developed 3D spheroids from each to investigate molecular targeted therapy combinations including CDK4/6 inhibitors (CDK4/6i) with AKT inhibitors (ATKi). Metastatic prostate cancer tissue was collected and three PDTX models were established and characterized using whole-exome sequencing. PDTX 3D spheroids were developed from these three PDTXs to show resistance patterns and test novel molecular-targeted therapies. CDK4/6i's were combined with AKTi's to assess synergistic antitumor response to prove our hypothesis that blockade of AKT overcomes drug resistance to CDK4/6i. This combination was evaluated in PDTX three-dimensional (3D) spheroids and in vivo experiments with responses measured by tumor volumes, PSA, and Ga-68 PSMA-11 PET-CT imaging. We demonstrated CDK4/6i's with AKTi's possess synergistic antitumor activity in three mCRPC PDTX models. These models have multiple unique pathogenic and deleterious genomic alterations with resistance to single-agent CDK4/6i's. Despite this, combination therapy with AKTi's was able to overcome resistance mechanisms. The IHC and Western blot analysis confirmed on target effects, whereas tumor volume, serum PSA ELISA, and radionuclide imaging demonstrated response to therapy with statistically significant SUV differences seen with Ga-68 PSMA-11 PET-CT. These preclinical data demonstrating antitumor synergy by overcoming single-agent CDK 4/6i as well as AKTi drug resistance provide the rational for a clinical trial combining a CDK4/6i with an AKTi in patients with mCRPC whose tumor expresses wild-type retinoblastoma 1.

9 August 2019 in Turkish Journal of Agriculture - Food Science and Technology
Verified
Journal Article
Open access
GAGöksen Çeçen Ayalp
Göksen Çeçen Ayalp
ÜÇÜlke Gülsüm Çalışkan
Ülke Gülsüm Çalışkan
ADAylin Alasonyalılar Demirer
Aylin Alasonyalılar Demirer
The aim of this study was to evaluate the clinic-histopathologic characteristics and to compare the morphometric measurements of healthy and subclinical laminitic claws of dairy cattle at different ages and weights. Non-lame 60 Holstein feet randomly collected from the slaughterhouse were evaluated. The effects of age, body-weight, claw location (right front lateal or right front medial etc), and presence of laminitis were investigated. The claws‘ conformation were evaluated morphometrically with ten measurements (toe length, toe height, outer and inner edges of the claw, heel height, the length of heel, the length of diagonal front wall, dorsal hoof angle, the width and the length of the sole). The claws were classified as normal or laminitic according to the histopathologic findings. The clinical findings of laminitis was confirmed on 71.2% of the claws (n=66). The toe length, toe height, the height of outer and inner edges of the claw, heel height, the length of heel, the length of diagonal front wall were smaller in laminitic claws. The dorsal hoof angle of healthy claws were bigger and statistically significant than the laminitic claws. Small haemorrhagic areas were determined in the parietal corium in the laminitic claws comparing to macroscopically healthy claws. The histopathologic characteristics of the corium of laminitic claws involve the hyperaemia, haemorrhages, oedema, thrombosis of capillaries and presence of mononuclear cell infiltration in dermis, stretching epidermal lamella, necrosis of epithelial cells and detachment of the lamellar basement membrane. According to this study results, contrary to literature, there was not a reliable relation between some changes in morphological structure of the claws and the presence of the laminitis were observed.

27 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJason Shirian
Jason Shirian
AHAlexandra Hockla
Alexandra Hockla
JGJustyna J. Gleba
Justyna J. Gleba
MCMatt Coban
Matt Coban
NRNaama Rotenberg
Naama Rotenberg
Julia M. ShifmanJulia M. Shifman
Julia M. Shifman
Matrix Metalloproteinases (MMPs) are drivers of many diseases including cancer and are established targets for drug development. Tissue inhibitors of metalloproteinases (TIMPs) are human proteins that inhibit MMPs and are being pursued for the development of anti-MMP therapeutics. TIMPs possess many attractive properties of a drug candidate, such as complete MMP inhibition, low toxicity and immunogenicity, high tissue permeability and others. A major challenge with TIMPs, however, is their formulation and delivery, as these proteins are quickly cleared from the bloodstream due to their small size. In this study, we explore a new method for plasma half-life extension for the N-terminal domain of TIMP2 (N-TIMP2) through appending it with a long intrinsically unfolded tail containing a random combination of Pro, Ala, and Thr (PATylation). We design, produce and explore two PATylated N-TIMP2 constructs with a tail length of 100- and 200-amino acids (N-TIMP2-PAT 100 and N-TIMP2-PAT 200 , respectively). We demonstrate that both PATylated N-TIMP2 constructs possess apparent higher molecular weights compared to the wild-type protein and retain high inhibitory activity against MMP-9. Furthermore, when injected into mice, N-TIMP2-PAT 200 exhibited a significant increase in plasma half-life compared to the non-PATylated variant, enhancing the therapeutic potential of the protein. Thus, we establish that PATylation could be successfully applied to TIMP-based therapeutics and offers distinct advantages as an approach for half-life extension, such as fully genetic encoding of the gene construct, mono-dispersion, and biodegradability. Furthermore, PATylation could be easily applied to N-TIMP2 variants engineered to possess high affinity and selectivity toward individual MMP family members, thus creating attractive candidates for drug development against MMP-related diseases.